文献速递青光眼神经眼科

烟酰胺联合丙酮酸治疗开角型青光眼二期随机试验中视野改善的地形学分析

A Topographical Analysis of Visual Field Improvement in a Phase 2 Randomized Trial of Nicotinamide and Pyruvate for Open-Angle Glaucoma.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

结果显示治疗组改善位点识别率显著高于安慰剂组(CMH合并OR=3.73,95%CI 2.36-5.89,P<0.001),改善沿弓形路径聚集,且与认知评分无关。

要点

  • 烟酰胺+丙酮酸组视野改善位点识别率显著高于安慰剂组(OR=3.73)。
  • 视野改善沿弓形路径聚集,位于中重度基线损害区域。
  • 贝叶斯模型估计治疗增加改善位点的后验概率为98.4%。

核心结论

  • 基于地形学斜率终点,烟酰胺联合丙酮酸治疗可显示局部弓形视野改善,该改善被全局指数遗漏且不能由认知变化解释。

主要发现

  • 烟酰胺+丙酮酸组改善位点识别率高于安慰剂组(Cochran-Mantel-Haenszel合并OR=3.73,95%CI 2.36-5.89,P<0.001)。
  • 总偏差差值敏感性分析结果一致(OR=5.08,95%CI 1.22-21.17,P=0.021)。
  • 改善聚集于弓形路径及中重度基线损害区域。
  • 贝叶斯模型估计治疗增加改善位点的后验概率为98.4%,RNFL先验仅适度佐证未实质优化推断。
  • 未发现与MoCA评分的关联。

关键数值与推荐

  • 改善位点定义为Huber稳健点对总偏差斜率在其基线严重度分层池化斜率分布中位于上十分位(≥90百分位)。

临床怎么用

  • 地形学斜率终点可揭示被全局指数遗漏的局部视野改善,适用于小样本早期神经保护试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to characterize topographical visual field (VF) improvement using pointwise total deviation (TD) slopes referenced to baseline severity, and to evaluate structure-function and cognitive associations in eyes receiving nicotinamide and pyruvate (NAM + PYR) treatment versus placebo. METHODS: This post hoc analysis used study-eye data from a phase 2 randomized trial of nicotinamide (3 g/day) plus pyruvate (3 g/day) versus placebo in open-angle glaucoma, with four baseline and four post-baseline VF visits. A location was improving if its Huber robust pointwise TD slope ranked in the upper decile (≥90th percentile) of the pooled slope distribution within its baseline-severity stratum. Bayesian hierarchical models assessed treatment effects, incorporating optical coherence tomography retinal nerve fiber layer (RNFL) slopes as structural priors; Montreal Cognitive Assessment (MoCA) scores tested for cognitive confounding. RESULTS: Thirty-two study eyes (21 receiving NAM + PYR, and 11 placebo) were analyzed. NAM + PYR treated eyes showed increased identification of improving locations versus placebo (Cochran-Mantel-Haenszel pooled odds ratio (OR) = 3.73, 95% confidence interval (CI) = 2.36-5.89, P < 0.001); a TD-difference sensitivity analysis was concordant (OR = 5.08, 95% CI = 1.22-21.17, P = 0.021). Improvement clustered along arcuate pathways and within moderate-to-deep baseline damage. The Bayesian model estimated a 98.4% posterior probability that NAM + PYR treatment increased improving locations; RNFL priors corroborated modestly but did not materially refine inference. No association was found with MoCA scores. CONCLUSIONS: Topographical, slope-based endpoints reveal localized arcuate VF improvement with nicotinamide and pyruvate that is missed by global indices and not explained by cognitive change. Bayesian modeling suits small early-phase neuroprotection trials, although structural priors added little over this short follow-up.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. De Moraes CG, Shukla AG, Cioffi GA, et al. A Topographical Analysis of Visual Field Improvement in a Phase 2 Randomized Trial of Nicotinamide and Pyruvate for Open-Angle Glaucoma. Invest Ophthalmol Vis Sci. 2026. PMID: 42517851. doi:10.1167/iovs.67.8.59

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。